Get the Stockscreener App
3.635
9.13%
-0.365
After Hours:
3.55
-0.085
-2.34%
Lyra Therapeutics Inc stock is traded at $3.635, with a volume of 51,641.
It is down -9.13% in the last 24 hours and down -6.31% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$4.00
Open:
$3.99
24h Volume:
51,641
Relative Volume:
0.98
Market Cap:
$6.45M
Revenue:
$770.00K
Net Income/Loss:
$-38.84M
P/E Ratio:
-0.2559
EPS:
-14.2049
Net Cash Flow:
$-43.02M
1W Performance:
-14.87%
1M Performance:
-6.31%
6M Performance:
-69.32%
1Y Performance:
-64.01%
1-Day Range:
$3.55
$4.00
1-Week Range:
$3.55
$4.23
52-Week Range:
$2.84
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
3.635 | 7.10M | 770.00K | -38.84M | -43.02M | -14.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Lyra Therapeutics Stock Rockets 56% With 6-Day Winning Streak - Trefis
Will Lyra Therapeutics Inc. stock pay special dividends2025 Trade Ideas & High Conviction Investment Ideas - Newser
Lyra Therapeutics (LYRA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Why Lyra Therapeutics Inc. stock is popular among millennials2025 Investor Takeaways & Expert Approved Momentum Ideas - Newser
Will Lyra Therapeutics Inc. stock benefit from infrastructure spendingQuarterly Earnings Summary & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-11-27 15:46:05 - moha.gov.vn
PERCEPTIVE ADVISORS LLC Reduces Stake in Lyra Therapeutics Inc - GuruFocus
Will Product Innovation Drive Hisar Spinning Mills Limited Stock in YEARRisk Management Strategies & Free Extraordinary Earning Power - earlytimes.in
Will Lyra Therapeutics Inc. stock deliver shareholder valueMarket Growth Summary & High Accuracy Trade Signal Alerts - newser.com
Can Lyra Therapeutics Inc. stock deliver sustainable ROEBull Run & Consistent Return Strategy Ideas - newser.com
What technical charts say about Lyra Therapeutics Inc. stockVolume Spike & Weekly Watchlist for Hot Stocks - newser.com
How to interpret RSI for Lyra Therapeutics Inc. stock2025 Short Interest & Stepwise Trade Signal Guides - newser.com
Will Lyra Therapeutics Inc. outperform the marketEarnings Risk Report & Detailed Earnings Play Alerts - newser.com
How to escape a deep drawdown in Lyra Therapeutics Inc.July 2025 Recap & Weekly Market Pulse Alerts - newser.com
Is Lyra Therapeutics Inc. stock in correction or buying zoneJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
Is Lyra Therapeutics Inc. stock overvalued by current metricsExit Point & Intraday High Probability Setup Alerts - newser.com
What machine learning models say about Lyra Therapeutics Inc.Trade Volume Report & AI Driven Stock Reports - newser.com
What valuation multiples suggest for Lyra Therapeutics Inc. stockJuly 2025 Levels & Weekly Return Optimization Alerts - newser.com
Risk adjusted return profile for Lyra Therapeutics Inc. analyzedMarket Weekly Review & Growth Focused Investment Plans - newser.com
Can a trend reversal in Lyra Therapeutics Inc. lead to recoveryWeekly Trade Report & Weekly Breakout Stock Alerts - newser.com
Lyra Therapeutics Faces Critical Juncture as Challenges Mount - Ad-hoc-news.de
What indicators show strength in Lyra Therapeutics Inc.2025 Market Sentiment & Free Safe Entry Trade Signal Reports - newser.com
Will earnings trigger a reversal in Lyra Therapeutics Inc.2025 Fundamental Recap & AI Based Buy and Sell Signals - newser.com
Major Shareholder Sells Thousands of Lyra Therapeutics Shares! - TipRanks
[Form 4] Lyra Therapeutics, Inc. Insider Trading Activity - Stock Titan
Lyra Therapeutics Narrows Losses And Plots New Drug Trial - Finimize
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):